Table V.
Association between Bcl-2 and DFS in the Danish Cohort of BIG 1 - 98 by multivariable analysis.a
| Risk factor | p-value | Level | n | Periodb | HR | (95% CI) |
|---|---|---|---|---|---|---|
| Bcl-2 | 0.004 | 0–9% | 37 | 2.11 | (1.30–3.42) | |
| 10–49% | 32 | 0.79 | (0.41–1.53) | |||
| ≥ 50%/weak-mod | 234 | 0–5 years | 1.20 | (0.89–1.63) | ||
| 5–10 years | 0.44 | (0.21–0.93) | ||||
| ≥ 50%/strong | 888 | 1.00 | (reference) | |||
| ER | 0.82 | 1–79% | 207 | 1.03 | (0.78–1.38) | |
| 80–100% | 984 | 1.00 | (reference) | |||
| Tumor grade | 0.004 | Not known | 159 | 1.22 | (0.70–2.12) | |
| Grade I | 249 | 0.72 | (0.52–1.00) | |||
| Grade II | 619 | 1.00 | (reference) | |||
| Grade III | 164 | 1.47 | (1.09–2.00) | |||
| Positive lymph nodes | 0.0001 | 0 | 416 | 0.70 | (0.53–0.93) | |
| 1–3 | 516 | 1.00 | (reference) | |||
| 4 + | 166 | 1.13 | (0.82–1.57) | |||
| 10 + | 93 | 3.05 | (2.18–4.27) | |||
| Histological type | 0.25 | Ductal | 999 | 1.00 | (reference) | |
| Non-ductal | 192 | 0.73 | (0.43–1.24) | |||
| Tumor size | 0.001 | 1–20 mm | 568 | 0.69 | (0.54–0.89) | |
| 21–50 mm | 585 | 1.00 | (reference) | |||
| ≥ 51 mm | 38 | 1.62 | (1.01–2.61) | |||
| HER-2 | 0.034 | normal | 1082 | 1.00 | (reference) | |
| amplified | 109 | 1.47 | (1.03–2.06) |
CI, confidence interval; ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2; HR, hazard ratio.
a
Model stratified by randomization option, allocated treatment and age at randomization.
b
Time-dependent variables. If nothing is mentioned the follow-up period is from 0 years after randomization.